Brokerages Set United Therapeutics Co. (NASDAQ:UTHR) Target Price at $382.08

Shares of United Therapeutics Co. (NASDAQ:UTHR) have been given a consensus recommendation of “Moderate Buy” by the twelve ratings firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $388.25.

UTHR has been the subject of a number of analyst reports. Argus upped their price target on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. LADENBURG THALM/SH SH raised their target price on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. The Goldman Sachs Group boosted their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. Oppenheimer raised their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Finally, UBS Group boosted their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a report on Wednesday, January 8th.

Insider Activity at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $371.05, for a total transaction of $3,710,500.00. Following the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at $956,195.85. This represents a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Louis W. Sullivan sold 26,209 shares of the stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the sale, the director now directly owns 5,051 shares in the company, valued at $1,885,134.22. This represents a 83.84 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 114,164 shares of company stock worth $41,671,293. Insiders own 11.90% of the company’s stock.

Hedge Funds Weigh In On United Therapeutics

Institutional investors have recently modified their holdings of the business. Wealthfront Advisers LLC grew its stake in United Therapeutics by 2,090,573.5% during the 4th quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company’s stock worth $6,462,018,000 after purchasing an additional 18,313,424 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of United Therapeutics by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 4,441,823 shares of the biotechnology company’s stock valued at $1,567,253,000 after buying an additional 32,213 shares during the period. FMR LLC grew its position in shares of United Therapeutics by 36.5% during the fourth quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company’s stock worth $519,170,000 after buying an additional 393,777 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of United Therapeutics by 4.0% during the fourth quarter. Geode Capital Management LLC now owns 1,138,292 shares of the biotechnology company’s stock worth $401,184,000 after buying an additional 44,277 shares during the period. Finally, AQR Capital Management LLC raised its holdings in United Therapeutics by 0.8% in the fourth quarter. AQR Capital Management LLC now owns 975,444 shares of the biotechnology company’s stock valued at $344,176,000 after acquiring an additional 7,710 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Trading Down 0.8 %

UTHR opened at $358.21 on Tuesday. United Therapeutics has a twelve month low of $221.53 and a twelve month high of $417.82. The firm has a market capitalization of $15.99 billion, a PE ratio of 15.73, a PEG ratio of 0.97 and a beta of 0.57. The firm’s 50-day moving average price is $362.39 and its 200 day moving average price is $360.91.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.